Association of Remdesivir Treatment With Mortality Among Hospitalized Adults With COVID-19 in the United States.

ABSTRACT:

Importance

SARS-CoV-2, which causes COVID-19, poses considerable morbidity and mortality risks. Studies using data collected during routine clinical practice can supplement randomized clinical trials to provide needed evidence, especially during a global pandemic, and can yield markedly larger sample sizes to assess outcomes for important patient subgroups.

Objective

To evaluate the association of remdesivir treatment with inpatient mortality among patients with COVID-19 outside of the clinical trial setting.

Design, setting, and participants

A retrospective cohort study in US hospitals using health insurance claims data linked to hospital chargemaster data from December 1, 2018, to May 3, 2021, was conducted among 24 856 adults hospitalized between May 1, 2020, and M

SUBMITTER: Chokkalingam AP 

PROVIDER: S-EPMC9716380 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature